The impact of rifaximin on the NHS hospital resource use associated with the management of patients with hepatic encephalopathy (HE): a retrospective observational study
Phase of Trial: Phase IV
Latest Information Update: 25 May 2017
Price : $35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms IMPRESS
- Sponsors Norgine
- 21 Apr 2017 According to a Norgine media release, data was presented at The International Liver Congress in April 2017.
- 02 Nov 2016 Results assessing the impact of rifaximin-aplha on the costs associated with hospital admissions and attendances in patients with Hepatic-encephalopathy, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 31 Oct 2016 Results published in Norgine media release.